Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis

Journal of Biomedical Materials Research - Part A

Volumn 89, Issue 2, 2009, Pages 281-292

  Chimote, G ^a   Banerjee, R ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Antitubercular drugs; Liposomes; Pulmonary tuberculosis; Twin impinger

Indexed keywords

ALVEOLAR DEPOSITION; ANTITUBERCULAR DRUGS; DIPALMITOYL PHOSPHATIDYLCHOLINE; DPPC LIPOSOME; DRUG CARRIER; ENTRAPMENT EFFICIENCY; ETHAMBUTOL; IN-VITRO; INHALABLE DRUG; PHYSICOCHEMICAL PROPERTY; PULMONARY SURFACTANTS; PULMONARY TUBERCULOSIS; SURFACTANT ACTION; SUSTAINED RELEASE; TWIN IMPINGER;

ADSORPTION; CHEMOTHERAPY; LIPOSOMES; PHOSPHOLIPIDS; SULFUR COMPOUNDS; SURFACE TENSION;

SURFACE ACTIVE AGENTS;

DIPALMITOYLPHOSPHATIDYLCHOLINE; ETHAMBUTOL; ISONIAZID; LIPOSOME; RIFAMPICIN; BIOMATERIAL; SURFACTANT; TUBERCULOSTATIC AGENT;

ARTICLE; ATELECTASIS; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; HUMAN; LUNG TUBERCULOSIS; NEBULIZATION; NEBULIZER; PHYSICAL CHEMISTRY; SURFACE TENSION; SUSTAINED DRUG RELEASE; ADSORPTION; ANIMAL; CAPILLARY; DRUG EFFECT; DRUG STABILITY; EVALUATION; INHALATIONAL DRUG ADMINISTRATION; MOUSE; PARTICLE SIZE;

ADMINISTRATION, INHALATION; ADSORPTION; ANIMALS; ANTITUBERCULAR AGENTS; BIOCOMPATIBLE MATERIALS; CAPILLARIES; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; LIPOSOMES; MICE; PARTICLE SIZE; SURFACE-ACTIVE AGENTS; TUBERCULOSIS, PULMONARY;

EID: 65549109778     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31959     Document Type: Article

References (42)

1. WHO report. Global tuberculosis control. Surveillance, planning, financing. WHO Report; Document WHO/CDS/TB/2002.295; 2002.
2. Selassie A, Pozsik C, Wilson D, Ferguson P. Why pulmonary tuberculosis recurs: A population based epidemiological study. Ann Epidemiol 2005;15:519-525.
3. 99mTc-tobramycin- surfactant mixture in rats with a Klebsiella pneumoniae lung infection. Appl Cardiopulm Pathophysiol 1998;7:87-94.
4. Haitsma JJ, Lachmann U, Lachmann B. Exogenous surfactant as a drug delivery agent. Adv Drug Deliv Rev 2001;47:197-207.
5. Kharash VS, Sweeney TD, Fredberg J, Lehr J, Damokosh AI, Avery MA, Brain JD. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 1991;144:909-913.
6. Saigal S, Robertson C, Sankaran K, Bingham W, Casiro O, MacMurray B, Whitfield M, Long W. One year outcome in 232 premature infants with birth weights of 750 to 1249 grams and respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air placebo. J Pediatr 1995;126:S61-S67.
7. Haagsman HP, Diemel RV. Surfactant-associated proteins: Functions and structural variation. Comp Biochem Physiol A Mol Integr Physiol 2001;129:91-108.
8. Nagarsenker MS, Londhe VY. Preparation and evaluation of a liposomal formulation of sodium cromoglicate. Int J Pharm 2003;251:49-56.
9. British Pharmacopoeia. Great Britain: British Pharmacopoeia, The Stationery Office; 2002.
10. King RJ, Clements JA. Surface active materials from dog lung. II. Composition and physiological correlations. Am J Physiol 1972;223:715-726.
11. Enhorning G. Pulmonary surfactant function studied with the pulsating bubble surfactometer (PBS) and the capillary surfactometer (CS). Comp Biochem Physiol A Mol Integr Physiol 2001;129:221-226.
12. European Pharmacopeian Secretariat. European Pharmacopoeia, 4th ed. Strasbourg: European Pharmacopeian Secretariat; 2004.
13. Hallworth GW, Westmoreland DG. The twin impinger: A simple device for assessing the delivery of drug from metered pressurized aerosol inhaler. J Pharm Pharmacol 1987;39:966-972.
14. Kendrick AH, Smith EC, Wilson RSE. Selecting and using nebulizer equipment. Thorax 1997;52:S92-S101.
15. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 1997;208:151-158.
16. ASTM active standards: F813-01 standard practice for direct contact cell culture evaluation of materials for medical devices.
17. Sharma P, Sharma JD. In vitro hemolysis of human erythrocytes-by plant extracts with antiplasmodial activity. J Ethnopharmacol 2001;74:239-243.
18. Hugli TE, Muller-Eberhard HJ. Anaphylatoxins: C3a and C5a. Adv Immunol 1978;26:1-53.
19. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2004;276:41-49.
20. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Bioequivalence trials of rifampicin containing formulations: Extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol Res 2004;50:317-327.
21. Rachana BR. Interactions between haematological derivatives and dipalmitoylphosphatidylcholine: Implications for adult respiratory distress syndrome. Colloids Surf B Biointerf 2004;34:95-104.
22. Veen AV, Mouton JW, Gommers D, Lachmann B. Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br J Pharmacol 1996;119:1145-1148.
23. Kharash VS, Sweeney TD, Fredberg J, Lehr J, Damokosh AI, Avery MA, Brain JD. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 1991;144:909-913.
24. Veen A, Mouton JW, Gommers D, Kluytmans JA, Dekkers P, Lachmann B. Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime and tobramycin. Antimicrob Agents Chemother 1995;39:329-333.
25. Chimote G, Banerjee R. Lung surfactant dysfunction in tuberculosis: Effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity. Colloids Surf B Biointerf 2005;45:215-223.
26. Pandey R, Sharma S, Khuller GK. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int J Antimicrob Agents 2004;23:414-415.
27. Leonenko Z, Fincot E, Vassiliev V, Amrein M. Effect of chlesterol on the physical properties of pulmonary surfactant films: Atomic force measurements study. Ultramicroscopy 2006;106:687-694.
28. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004;269:37-49.
29. Rachana BR. Effects of albumin and erythrocyte membranes on spread monolayers of lung surfactant lipids. Colloids Surf B Biointerf 2006;50:9-17.
30. Schreier H, Ricardo J, Rothi G, Stecenko AA. Pulmonary delivery of liposomes. J Control Release 1993;24:209-223.
31. Suarez S, Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm Res 2001;18:1315-1319.
32. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001;18:1405-1410.
33. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly(DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-986.
34. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54:761-766.
35. Tomoda K, Kojima S, Kajimoto M, Watanabe D, Nakajima T, Makino K. Effects of pulmonary surfactant system on rifampicin release from rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerf 2005;45:1-6.
36. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005;85:227-234.
37. Hall SB, Lu RZ, Venkitaraman AR, Hyde RW, Notter RH. Inhibition of pulmonary surfactant by oleic acid: Mechanisms and characteristics. J Appl Physiol 1992;72:1708-1716.
38. Chimote G, Banerjee R. Effect of antitubercular drugs on dipalmitoylphosphatidylcholine monolayers: Implications for drug loaded surfactants. Respir Physiol Neurobiol 2005;145:65-77.
39. Brain JD, Valberg PA. Deposition of aerosol in the respiratory tract. Am Rev Resp Dis 1979;120:1325-1373.
40. Enhorning G, Duffy LC, Welliver RC. Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995;151:554-556.
41. Schaad UB, Krucko WJ, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987;111:599-605.
42. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG, Hall WJ. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983;308:1443-1447.